Search
Search filters
Type
Audience
Category
Issue
Last updated
Displaying 1 - 15 of 20 items.
Health Canada is updating the labels of the Janssen and Vaxzevria (AstraZeneca) COVID-19 vaccines
AlertPublic advisory | 2021-11-09
Adverse events in Europe following immunization with the AstraZeneca COVID-19 vaccine
AlertPublic advisory | 2021-03-11
Archived - For the Public - Important Safety Information on IRESSA (gefitinib) - AstraZeneca Canada Inc.
AlertHealth professional risk communication | 2007-05-14
Archived - Important Safety Information on IRESSA® (gefitinib) 250 mg Tablets - AstraZeneca Canada Inc.
AlertInformation update | 2005-08-26
Archived - Public Advisory: Liver Problems Associated With Use of ACCOLATE (zafirlukast) in Some Patients - AstraZeneca - For the Public
AlertHealth professional risk communication | 2002-12-18
Archived – Important Safety Information Concerning Liver Problems for Patients Taking ACCOLATE® (Zafirlukast) – AstraZeneca Canada Inc. – For the Public
AlertHealth professional risk communication | 2004-04-19
Archived – Health Canada advises to stop using AstraZeneca Xylocaine 2% Jelly Single Use Plastic Syringes due to potential health risks
AlertPublic advisory | 2006-09-27
Archived – Important Safety Information Regarding Medication Errors Resulting From Confusion Between Seroquel and Serzone-5HT2 – AstraZeneca and Bristol-Myers Squibb – For the Public
AlertHealth professional risk communication | 2002-10-31
Pulmicort Turbuhaler (budesonide) powder for oral inhalation - Potential device failure - For the Public
AlertHealth professional risk communication | 2012-07-26
CAPRELSA (vandetanib) - Serious Risk of Abnormal Heart Rhythm - For the Public
AlertHealth professional risk communication | 2012-02-15
Archived - Safety information regarding topical anesthetics and serious adverse events - For the Public
AlertHealth professional risk communication | 2009-03-05
Archived - For the Public - Important Safety and Efficacy Information on Iressa (gefitinib) 250 mg Tablets
AlertHealth professional risk communication | 2006-08-26
Archived - Important Safety Concerns re Use of Propofol for Sedation in Pediatric Patients
AlertHealth professional risk communication | 2001-05-01
Archived - Association of CRESTOR
AlertHealth professional risk communication | 2005-03-08
Archived – Important Safety Information Regarding Casodex 150 mg – Accelerated Deaths in Localized Prostate Cancer Patients – For the Public
AlertHealth professional risk communication | 2003-08-26